Dance Biopharm Announces Rebranding to Aerami Therapeutics Reflecting a Broadened Strategic Focus on Inhaled Therapies for Chronic Diseases


You May Also Like

CytomX Therapeutics Announces Presentations at 2018 ASCO Annual Meeting

- Preliminary first-in-human data to be presented from PROCLAIM-CX-072 trial of a PD-L1 Probody ...

SELLAS Life Sciences Provides Galinpepimut-S and Nelipepimut-S Program Update

Dr. Richard Maziarz and Dr. Roisin O'Cearbhaill Named Co-Principal Investigators for Galinpepimut-S (GPS) – ...